August 26, 2015 / Universidad de Kyushu / Informes Científicos
Texto/Wu Tingyao
The research team of Kuniyoshi Shimizu, an associate professor at the Institute of Agricultural Sciences of Kyushu University in Japan, confirmed that 31 triterpenoids isolated from the fruiting body of Ganoderma inhibit the neuraminidase of five influenza A viruses to varying degrees, among which there are two triterpenoids even suitable for development as anti-influenza drugs. The research results were published in “Scientific Reports” under the “Nature” publishing group at the end of August 2015.
Neuraminidase is one of the two proteins protruding on the surface of influenza A viruses. Each influenza virus has about one hundred of these proteases. When the virus invades the cell and uses the material in the cell to replicate new virus particles, neuraminidase is needed for the new virus particles to break away from the cell and further infect other cells. Por lo tanto, when neuraminidase loses its activity, the new virus will be locked in the cell and cannot escape, the threat to the host will be reduced, and the disease can be controlled. The commonly used oseltamivir (Tamiflu) in clinical practice is to use this principle to prevent the proliferation and spread of the virus.
According to research conducted by Kuniyoshi Shimizu, at a concentration of 200 μM, these Ganoderma triterpenoids inhibited the activity of H1N1, H5N1, H7N9 and two resistant mutant strains NA (H1N1, N295S) and NA (H3N2, E119V) to varying degrees. On the whole, the inhibitory effect on neuraminidase of N1 type (especially H5N1) is the best, and the inhibitory effect on neuraminidase of H7N9 is the worst. Among these triterpenoids, ganoderic acid TQ and ganoderic acid TR showed the highest levels of inhibition, and the effects of these two compounds ranged from 55.4% a 96.5% inhibition for different NA subtypes.
Further analysis of the structure-activity relationship of these triterpenoids revealed that the triterpenoids, which have a better inhibitory effect on N1 neuraminidase, have the main structure of “tetracyclic triterpenoids with two double bonds, a branch as a carboxylic group, and an oxygen-containing group at the R5 site” (Backbone A in the figure below). If the main structure is the other two (Backbone B and C in the figure below), the effect will be poor.
(Source/Sci Rep. 2015 Ago 26;5:13194.)
In silico docking is used to simulate the interaction of ganoderic acids (T-Q and TR) and neuraminidases (H1N1 and H5N1). Como resultado, it was found that both ganoderic acids and Tamiflu were able to directly bind to the active area of neuraminidase. This active area is composed of several amino acid residues. Ganoderma acids TQ and TR will bind to the two amino acid residues Arg292 and Glu119. Tamiflu has another option but can also make neuraminidase ineffective.
Compared with inhibiting other proteins on the influenza virus (such as the M2 protein, which opens the virus shell at the moment the virus binds to the host cell and sends the viral genes to the cell), neuraminidase inhibitors are currently recognized as effective and less resistant influenza treatment drugs. Por lo tanto, researchers believe that ganoderic acids T-Q and TR, which are similar to but not the same in the mechanism of Tamiflu, have the opportunity to be used as a new generation of anti-influenza drugs or design references.
Sin embargo, there is a prerequisite for the drug to be used as an anti-influenza drug, eso es, the drug must effectively inhibit the reproduction of the virus without harming the cells infected by the virus. Sin embargo, in experiments on cells infected with live viruses and breast cancer cell lines (MCF-7), it was found that when the researchers used these two types of ganoderic acids alone, they had doubts about high cytotoxicity, but they also found another kind of Ganoderma triterpenoid, ganoderol B, has an inhibitory effect on H5N1 (but the inhibitory effect is poor), but it is not cytotoxic. Por lo tanto, researchers believe that how to improve the safety of ganoderic acids T-Q and TR through modification of the chemical structure while still retaining their inhibition of neuraminidase activity must be carefully considered.
[Fuente] Zhu Q, et al. Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design. Representante de ciencia. 2015 Ago 26;5:13194. doi: 10.1038/srep13194.
FIN
Sobre el autor/ ms. Wu Tingyao
Wu Tingyao ha estado brindando información de primera mano sobre Ganoderma desde 1999. Ella es la autora de Curación con ganoderma (Publicado en People’s Medical Publishing House en abril 2017).
★ Este artículo se publica bajo la autorización exclusiva del autor.
★ Los trabajos anteriores no se pueden reproducir, extraído o utilizado de otras maneras sin la autorización del autor.
★ Por violaciones de la declaración anterior, el autor perseguirá las responsabilidades legales pertinentes.
★ El texto original de este artículo fue escrito en chino por Wu Tingyao y traducido al inglés por Alfred Liu. Si hay alguna discrepancia entre la traducción (Inglés) y el original (Chino), El chino original prevalecerá. Si los lectores tienen alguna pregunta, Póngase en contacto con el autor original, EM. Wu Tingyao.
